BioXcel Therapeutics
A clinical-stage biopharmaceutical company developing medicines in neuroscience and immuno-oncology, utilizing artificial intelligence.
The USA-based company uses big data and proprietary machine learning algorithms to identify new therapeutic indices.
Its two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally-administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno oncology agents.
Latest BioXcel Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze